Effectiveness of Generic Tofacitinib in the Treatment of Patients with Mild Alopecia Areata in China: A Retrospective Real-World Study

Abstract

Keywords

alopecia areata JAK inhibitor generic tofacitinib effectiveness real-world

Get full access to this article

View all access options for this article.

References

Meah

Wall

York

, et al. The Alopecia Areata Consensus of Experts (ACE) study part II: results of an international expert opinion on diagnosis and laboratory evaluation for alopecia areata. J Am Acad Dermatol. 2021;84(6):1594-1601.

King

Craiglow

. Janus kinase inhibitors for alopecia areata. J Am Acad Dermatol. 2023;89(2 Suppl):S29-S32.

Jian

Qian

, et al. Effectiveness and safety of generic tofacitinib in alopecia areata: is the generic a cost-effective option? A retrospective study. Arch Dermatol Res. 2024;316(5):154.

Kennedy Crispin

Craiglow

, et al. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. JCI Insight. 2016;1(15):e89776.

Liu

Craiglow

Dai

King

. Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients. J Am Acad Dermatol. 2017;76(1):22-28.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.03 MB

52.00 MB